Madison Clarke
China is the world's most populous country and has a lucrative vaccine industry, with an estimated 55 different types of vaccines, protecting against 28 types of individual infectious microbial diseases. China produces approximately 700 million vaccine doses annually, making it one of the world's largest producers of vaccines. China's National Regulatory system for vaccines has passed assessments by the World Health Organization (WHO), indicating that its vaccine regulatory oversight meets international standards. However, there have been concerns about the safety and effectiveness of Chinese-made vaccines, particularly with the COVID-19 vaccines, CoronaVac and Sinopharm. While these vaccines have been administered to several billion people in over 100 countries, there have been rumours and misinformation about their efficacy, especially among older citizens. Nevertheless, China's vaccine industry has achieved significant milestones, such as polio eradication, hepatitis B control, and tetanus elimination, and continues to play a crucial role in global health by providing affordable and accessible vaccines.
| Characteristics | Values |
|---|---|
| Number of vaccine manufacturers | 34 (4 international joint ventures, 7 state-run, and 23 private) |
| Number of major manufacturers | 21 |
| Annual vaccine production | 700 million doses |
| Total number of vaccines produced | 55 different types |
| Number of diseases vaccines protect against | 28 |
| Leading manufacturer | China National Biotec Group (CNBG) |
| Supply volume between 2007 and 2015 | 666 million to 1.19 billion doses |
| Number of Chinese-made COVID-19 vaccines delivered internationally between 2020 and 2022 | N/A |
| Number of COVID-19 vaccines administered worldwide in 2021 | About half |
Explore related products
$11.93 $21.99
What You'll Learn
China's vaccine industry is lucrative due to its large population
China is one of the world's most populous countries, with over 1.4 billion people. Its vaccine industry is a lucrative market for healthcare manufacturers due to its large population. The country has a high disease burden, and its recent uplifting of the one-child policy has shifted the demographic, making vaccines even more important. China's National Regulatory system for vaccines passed assessments by the World Health Organization (WHO) in 2011 and 2014, indicating that its vaccine regulatory oversight meets international standards.
China's vaccine industry is one of the largest globally, with an annual production of over 1 billion doses. The country has become a leading developer of affordable vaccines against diseases such as hepatitis E and Japanese encephalitis, crucial for developing countries in Southeast Asia and the Western Pacific regions. China's immunization program has achieved significant successes, including polio eradication by 2000, a 97% reduction in hepatitis B infections among young children, and a more than 99% decrease in measles incidence.
The country's vaccine industry is characterized by stringent manufacturing laws and regulations, which have hindered foreign manufacturers from entering the market. Domestic vaccine firms supplied 98.6% of government-provided category 1 vaccines and 90.3% of self-paid category 2 vaccines between 2007 and 2015. The government has attempted to make the most common vaccines, such as DTP, MMR, hepatitis A and B, meningococcal, and polio vaccines, compulsory and readily accessible for newborns and children up to 14 years old.
China's vaccine industry has faced challenges, including incidents of substandard, counterfeit, or expired vaccines distributed to the public, leading to infant fatalities and side effects among children. The Chinese government has responded by implementing stricter controls and tougher sanction measures, such as the Vaccine Administration Law in December 2019. China has also successfully developed COVID-19 vaccine products, with CoronaVac and Sinopharm being administered to several billion people in over 100 countries. These vaccines use traditional inactivated vaccine technology and have been widely adopted domestically and exported worldwide, mainly to developing countries.
Antibodies: How They Attack Pathogens
You may want to see also
Explore related products
China's vaccines are safe and effective, according to the WHO
China is one of the world's largest producers of vaccines, manufacturing approximately 700 million vaccine doses annually. The country has 34 vaccine manufacturers, including four international joint ventures, seven state-run, and the rest are private. China's vaccine regulatory oversight meets World Health Organization (WHO) standards, with the National Regulatory system for vaccines passing assessments by the WHO in 2011 and 2014.
Despite the country's significant achievements in vaccine development and production, China's Expanded Program on Immunization (EPI) system protects children from fewer diseases than many high- and middle-income countries. Notably, vaccines for Hib, ORV, PCV, influenza, and HPV are unavailable in China's EPI system, although they are recommended by the WHO for all countries' national immunization programs. However, China's immunization program has successfully eradicated polio, reduced the prevalence of chronic hepatitis B infection among young children by 97%, and decreased the annual incidence of measles by more than 99%.
China has also made substantial progress in the manufacture of inactivated COVID-19 vaccines, with several Chinese pharmaceutical companies developing their own inactivated vaccines that have completed clinical trials with positive results. The WHO has approved some Chinese-made COVID-19 vaccines, such as the Sinopharm vaccine produced by a Chinese state-owned company and the Sinovac vaccine. These vaccines have been widely adopted domestically and exported worldwide, mainly to developing countries.
While China's vaccine industry has experienced setbacks, such as incidents of substandard or counterfeit vaccines, the government has implemented reforms to improve vaccine safety and quality. The growth of China's vaccine industry is a positive development for global health, as it increases the availability and affordability of vaccines, benefiting people worldwide.
Hepatitis B Vaccine: Effective Protection and Prevention
You may want to see also
Explore related products
China's COVID-19 vaccines have been widely adopted
China is one of the world's most populous countries, and its vaccine industry is a lucrative market for healthcare manufacturers. China produces approximately 700 million vaccine doses annually, making it one of the world's largest producers of vaccines. China's National Regulatory system for vaccines passed assessments by the World Health Organization (WHO) in 2011 and 2014, indicating that China's vaccine regulatory oversight meets international standards.
China's COVID-19 vaccines, CoronaVac and Sinopharm, have been widely adopted both domestically and internationally. By December 2022, Chinese-made COVID-19 vaccines had been delivered internationally to over 100 countries, making up about half of all shots administered worldwide in 2021. These vaccines are not mRNA vaccines like those manufactured by Pfizer and Moderna but instead use a well-proven, traditional inactivated vaccine technology. CoronaVac, for example, contains an inactivated or killed form of the SARS-CoV-2 virus. Phase 3 clinical trials for CoronaVac have been completed in several countries, including Brazil, Turkey, and Indonesia, with an overall efficacy rate ranging from 50 to 90% depending on the dosing regimen and trial location.
Despite the wide adoption of China's COVID-19 vaccines, there have been concerns about their effectiveness and safety, particularly for elderly citizens. These concerns have been fuelled by rumours and misinformation, especially on social media, with some physicians in China also unsure if the vaccines are safe for the elderly. However, according to Ben Cowling, an epidemiologist at the University of Hong Kong, the Chinese vaccines offer just as much protection against severe disease as the mRNA vaccines.
China's COVID-19 vaccination strategy has impacted the global pandemic, strengthening China's opportunities and capabilities to participate in global development and enhancing the equity of vaccines. The National Health Commission of China has emphasized that the country encourages voluntary vaccination against COVID-19 and strives to ensure that all eligible individuals have access to the vaccine. However, in the mobilization and vaccination process, some local governments have adopted extreme one-size-fits-all policies, and individual discordant phenomena have been observed.
Cat Vaccinations: Annual Vet Visits, Necessary?
You may want to see also
Explore related products
China's vaccine industry has had issues with substandard products
China is one of the world's largest producers of vaccines, manufacturing approximately 700 million doses annually. The country has 34 vaccine manufacturers, of which four are international joint ventures, seven are state-run, and the rest are private. China's National Regulatory system for vaccines has passed assessments by the World Health Organization (WHO) in 2011 and 2014, indicating that its vaccine regulatory oversight meets international standards. WHO has also expressed confidence in the quality, safety, and effectiveness of vaccines made in China.
However, China's vaccine industry has faced challenges in recent years, with several incidents of substandard, counterfeit, or expired vaccines being distributed to the public. One notable case is the 2018 Changchun Changsheng vaccine incident, where the company was charged with manufacturing and selling substandard diphtheria-tetanus-acellular-pertussis (DTaP) vaccines and illegally producing freeze-dried rabies vaccines. This incident had a significant impact on public confidence in vaccines, with many parents becoming skeptical about vaccinating their children.
In response to these scandals, the Chinese government has implemented stricter controls and tougher sanction measures in the vaccine industry. The Vaccine Administration Law came into force in December 2019, bringing stricter oversight to the sector. The government has also reformed measures to monitor and control vaccine supply chains, and companies involved in scandals, such as Changsheng, have faced significant fines and disciplinary actions.
While China has taken steps to address the issues with substandard vaccines, the incidents have had lasting effects on public trust. The scandals have led to a decline in vaccination rates and an increase in medical tourism abroad as parents seek alternative options for inoculating their children. The Chinese government continues to work towards restoring confidence in its vaccine industry by enhancing regulatory frameworks and ensuring vaccine quality and efficacy.
Protecting Yourself: TDAP Vaccine Frequency
You may want to see also
Explore related products
China's vaccines protect against many diseases
China is one of the world's largest producers of vaccines, manufacturing approximately 700 million doses annually. The country has a large domestic manufacturing base capable of producing a large quantity of vaccines at low prices, making them accessible to all eligible children free of charge. China's National Regulatory system for vaccines has passed assessments by the World Health Organization (WHO), indicating that its vaccine regulatory oversight meets international standards.
China's immunization program has achieved significant milestones in the past two decades, including polio eradication, hepatitis B control, and tetanus elimination. The prevalence of hepatitis B virus in children under five years dropped from 9.7% in 1992 to 0.3% in 2014 due to neonatal hepatitis B vaccination. Similarly, the annual incidence of measles has seen a steep decline, dropping from over 9 million cases in the mid-1990s to below 6,000 in 2017. Since 2006, no cases of diphtheria have been reported in China.
Through its Expanded Program on Immunization (EPI), China has made common vaccines like DTP (Diphtheria, Tetanus, Pertussis), MMR (Measles, Mumps, and Rubella), hepatitis A and B, meningococcal, and polio vaccines compulsory and readily accessible. However, China's EPI system offers protection against fewer diseases than many high-income and middle-income countries, lacking vaccines such as Hib, ORV, PCV, influenza, and HPV.
During the COVID-19 pandemic, several Chinese companies successfully developed COVID-19 vaccine products, including CoronaVac and Sinopharm, which have been administered to several billion people in over a hundred countries. These vaccines use traditional inactivated vaccine technology, containing a killed form of the SARS-CoV-2 virus. While they are considered less effective than mRNA vaccines, studies have shown that they offer comparable protection against severe disease, especially for adults under 60.
In summary, China's vaccines protect against various diseases, and the country has made significant strides in vaccine development and accessibility. However, there have been challenges, including past incidents of substandard or counterfeit vaccines, which have led to reforms in the vaccine supply chain to ensure better quality control.
Vaccine Exemptions: Kids' Rights in Public Schools
You may want to see also
Frequently asked questions
China is one of the world's largest producers of vaccines, with an estimated annual production capacity of over 1 billion doses. China presently has a total of 41 vaccine manufacturing companies, of which 21 are major manufacturers. However, not all vaccines are made in China.
China's National Regulatory system for vaccines has passed assessments by the World Health Organization (WHO) in 2011, 2014, and 2019, indicating that China's vaccine regulatory oversight meets international standards. WHO has also pre-qualified some Chinese-made vaccines, deeming them consistently safe, effective, and of high quality. However, there have been concerns and skepticism about the safety of Chinese-made COVID-19 vaccines, especially for the elderly, and issues with past vaccines have made segments of the population wary.
China produces a large number of vaccines, presently estimated at 55 different types, which protect against 28 types of individual infectious microbial diseases. Some examples include DTP (Diphtheria, Tetanus, Pertussis), MMR (Measles, Mumps, Rubella), hepatitis A and B, meningococcal, polio, and COVID-19 vaccines.
No, Chinese-made vaccines are also exported worldwide, mainly to developing countries. Three vaccines have been prequalified by WHO, enabling their procurement by UNICEF and GAVI for use in other countries.
With China entering the global vaccine market, competition is expected to increase, driving down prices and making vaccines more affordable for governments and international procurement agencies.
